Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
Gonzalez Patricia Paola reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Patricia Paola Gonzalez received a grant of 321 Stock Equivalent Units as director compensation. These units were credited on March 31, 2026 at a reference value of $102.67 per unit and track the value of Abbott common shares.
The grant increased her balance to 5,558 Stock Equivalent Units, including amounts accumulated through a dividend reinvestment feature. The units are held in a grantor trust and are generally paid in cash around age 65 or upon retirement from the board, rather than being traded in the open market.
Alpern Robert J reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Robert J. Alpern received a grant of 76 stock equivalent units on March 31, 2026 as part of his director compensation. These units are valued at $102.67 per unit and track the return of Abbott common shares.
The units are credited to a stock equivalent unit account in a grantor trust established by the director and are generally paid out in cash at age 65 or upon retirement from the board. After this award and dividend reinvestment activity, his balance totals 10,544 stock equivalent units in this account.
Ahuja Nita reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Nita Ahuja received a grant of stock equivalent units as part of her board compensation. On this Form 4, she was awarded 102 stock equivalent units, each priced at $102.67, credited to a stock equivalent unit account.
The footnote explains these director fees are credited to the account and generally paid in cash at age 65 or upon retirement from the board, earning the same return as if invested in Abbott common shares. Following this grant, her reported balance in this account is 102 stock equivalent units.
Abbott Laboratories received an amended Schedule 13G/A from The Vanguard Group stating that, following an internal realignment, Vanguard and certain subsidiaries will report beneficial ownership separately. The filing lists Amount beneficially owned: 0 shares and Percent of class: 0% with an effective date shown as 03/13/2026.
ORVILLE JACOB A reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES Senior Vice President Orville Jacob A received a grant of 13,255 common shares as a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 2-year term, with one-half vesting in any one year beginning on March 23, 2027.
Following this grant, he directly holds 50,493 common shares. The award includes the right to have shares withheld to cover tax obligations rather than paying taxes in cash.
ABBOTT LABORATORIES Senior Vice President Orville Jacob A filed an initial ownership report showing 37,238 common shares held directly. These shares represent a restricted stock unit award with a four-year term, vesting in equal annual installments starting on February 25, 2027, with the ability to have shares withheld for taxes.
The report follows Abbott’s acquisition of Exact Sciences Corporation, where each Exact common share was converted into the right to receive $105.00 in cash. Certain Exact restricted stock units were assumed by Abbott and converted into Abbott restricted stock units based on this merger consideration and Abbott’s 10-day average share price before closing.
Abbott Laboratories has completed its acquisition of Exact Sciences, making Exact a wholly owned subsidiary focused on cancer screening and diagnostics. Each Exact Sciences common share was converted into the right to receive $105.00 in cash at closing. Exact’s last trading day on Nasdaq was March 20, 2026. The deal adds leading products such as Cologuard, Oncotype DX, Oncodetect and Cancerguard, and expands Abbott’s presence in U.S. cancer screening and precision oncology diagnostics, which the company cites as a $60 billion market.
Abbott Laboratories is asking shareholders to vote on five items at its 2026 Annual Meeting, including electing 12 directors, ratifying Ernst & Young as auditors, approving executive pay on an advisory basis, and adopting new 2026 incentive and non‑U.S. employee stock purchase plans.
The proxy highlights strong long-term performance, with 2025 total shareholder return of 13% versus a 7% peer median, and three‑ and five‑year TSR of 21% and 25%, both above peers. Abbott returned $5 billion to shareholders in 2025 and raised its dividend by 6.8%, its 54th consecutive annual increase.
The board stresses governance, noting that 11 of 12 nominees are independent, all directors are elected annually by majority vote, and committees are fully independent. The company also emphasizes sustainability and human capital goals, including a 2030 plan to expand access to healthcare, cut emissions, and build a diverse, future-ready workforce.
Abbott Laboratories completed a major debt financing, issuing $20 billion of senior notes in multiple tranches maturing between 2029 and 2066, including fixed-rate coupons from 3.700% to 5.600% and a floating-rate 2029 series.
Abbott plans to use the net proceeds, along with cash and possible additional borrowings, to fund the acquisition of Exact Sciences Corporation, repay Exact Sciences’ debt, cover related fees and expenses, and for general corporate purposes such as debt repayment. If the Exact Sciences acquisition is not completed by a deadline tied to the merger agreement’s End Date, or Abbott abandons the deal, Abbott must redeem all outstanding notes at 101% of principal plus accrued interest under a special mandatory redemption feature.